enGene Therapeutics Inc.
Business
enGene Therapeutics is a clinical-stage biotechnology company developing non-viral genetic medicines for mucosal tissues and systemic indications, with a lead program in non-muscle invasive bladder cancer (NMIBC). The company's lead product candidate, detalimogene voraplasmid, is a genetic medicine delivered via its proprietary DDX (dually derived chitosan) platform, designed to activate immune responses against bladder tumors. enGene is conducting the Phase 1/2 LEGEND trial and evaluates commercialization strategy for detalimogene independently in the United States and through selective international partnerships.
Summary from 10-K filed 2025-12-22
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 |
|---|---|---|---|---|---|
| Research and development | 94 | 38 | 16 | 15 | |
| General and administrative | 29 | 24 | 10 | 4 | |
| Total operating expenses | 123 | 62 | 26 | 19 | |
| Loss from operations | 123 | 62 | 26 | 19 | |
| Interest income | −9 | −10 | −1 | −129,000 | |
| Interest expense | 3 | 3 | 5 | — | |
| Gain on extinguishment of debt | 0 | 366,000 | 3 | — | |
| Other expenses (income), net | 569,000 | 113,000 | 129,000 | 662,000 | |
| Total other income, net | −6 | −7 | 74 | 5 | |
| Net loss before income taxes | 117 | 55 | 100 | 24 | |
| Provision for (recovery of) income taxes | 0 | −19,000 | 17,000 | 22,000 | |
| Net loss | 117 | 55 | 100 | 24 | |
| Unrealized (gain) loss on available-for-sale investments | −531,000 | −403,000 | — | — | |
| Total comprehensive loss | 117 | 55 | 100 | 23 | |
| Net loss per share of common shares, basic | 2.29 | 1.46 | 151.22 | 44.3 | |
| Net loss per share of common shares, diluted | 2.29 | 1.46 | 151.22 | 44.3 | |
| Weighted-average common shares outstanding, basic | 51 | 38 | 692,609 | 655,153 | |
| Weighted-average common shares outstanding, diluted | 51 | 38 | 692,609 | 655,153 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 50 | 173 | 82 | 20 | — | |
| Marketable securities - short term | 144 | 65 | — | — | — | |
| Restricted investments | 79,000 | 72,000 | 76,000 | 74,000 | — | |
| Investment tax credits receivable | 927,000 | 332,000 | 2 | 1 | — | |
| Prepaid and other current assets | 7 | 9 | 2 | 739,000 | — | |
| Total current assets | 201 | 247 | 85 | 23 | — | |
| Marketable securities - long term | 9 | 60 | — | — | — | |
| Property and equipment, net | 2 | 1 | 589,000 | 387,000 | — | |
| Operating lease right of use assets | 8 | 2 | — | — | — | |
| Other assets | 1 | 1 | 930,000 | 939,000 | — | |
| Total assets | 221 | 311 | 87 | 24 | — | |
| Accounts payable | 7 | 1 | 1 | 723,000 | — | |
| Accrued expenses and other current liabilities | 15 | 12 | 4 | 3 | — | |
| Operating lease liabilities, current | 2 | 423,000 | — | — | — | |
| Current portion of note payable | 8 | 699,000 | 562,000 | 1 | — | |
| Total current liabilities | 32 | 15 | 5 | 5 | — | |
| Note payable, net of current portion | 15 | 22 | 9 | 10 | — | |
| Operating lease liabilities, net of current portion | 6 | 1 | — | — | — | |
| Liabilities, Total | 54 | 39 | 14 | 47 | — | |
| Common shares, no par value; unlimited shares authorized, 52,018,658 and 50,976,676 shares issued and outstanding as of October 31, 2025 and October 31, 2024, respectively. | 513 | 510 | 259 | 16 | — | |
| Additional paid-in capital | 27 | 19 | 14 | 8 | — | |
| Accumulated other comprehensive loss | −888,000 | −1 | −1 | −1 | — | |
| Accumulated deficit | −372 | −255 | −200 | −100 | — | |
| Total shareholder's equity | 168 | 273 | 72 | −77 | −53 | |
| Total liabilities and shareholder's equity | 221 | 311 | 87 | 24 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 |
|---|---|---|---|---|---|
| Net loss | −117 | −55 | −100 | −24 | |
| Non-cash interest expense | 854,000 | 806,000 | 778,000 | 644,000 | |
| Non-cash lease expense | 378,000 | 163,000 | — | −5,000 | |
| Loss on the disposal of property and equipment | — | 22,000 | — | — | |
| Net amortization of premiums (accretion of discounts) on marketable securities | −3 | −232,000 | — | — | |
| Unrealized foreign currency losses (gains) | 3,000 | −6,000 | 489,000 | — | |
| Share-based compensation expense | 10 | 5 | 3 | 116,000 | |
| Depreciation of property and equipment | 509,000 | 323,000 | 175,000 | 238,000 | |
| Investment tax credit receivable | −595,000 | 2 | −1 | 143,000 | |
| Prepaid expenses and other assets | 2 | −8 | −751,000 | −113,000 | |
| Accounts payable | 5 | 474,000 | 373,000 | −197,000 | |
| Accrued expenses and other current liabilities | 3 | 5 | 868,000 | 2 | |
| Lease liabilities | 274,000 | −49,000 | — | — | |
| Net cash used in operating activities | −99 | −48 | −25 | −18 | |
| Purchases of property and equipment | −1 | −925,000 | −318,000 | −153,000 | |
| Purchases of marketable securities | −161 | −125 | — | — | |
| Proceeds from maturities of marketable securities | 137 | — | — | — | |
| Net cash used in investing activities | −25 | −126 | −318,000 | −153,000 | |
| Payment of Reverse Recapitalization and PIPE Financing costs | — | −613,000 | −10 | — | |
| Proceeds from the February 2024 PIPE Financing | — | 260 | 57 | — | |
| Payments of issuance costs associated with the 2024 PIPE Financing | — | −12 | — | — | |
| Proceeds from exercise of common share warrants | — | 6 | — | — | |
| Proceeds from exercise of stock options | 2 | 113,000 | 44,000 | 12,000 | |
| Repayments of term loan principal | −699,000 | −9 | −2 | — | |
| Proceeds from issuance of term loan | — | 23 | — | 11 | |
| Payments of debt issuance costs associated with the term loan | — | −585,000 | — | −391,000 | |
| Net cash provided by financing activities | 2 | 266 | 86 | 28 | |
| Effect of exchange rate changes on cash | 1,000 | 1,000 | 1,000 | −805,000 | |
| Net (decrease) increase in cash and cash equivalents | −123 | 91 | 61 | 9 | |
| Cash paid for interest | 2 | 2 | 1 | 615,000 | |
| Reverse Recapitalization and PIPE financing transaction costs included within accrued expenses | — | 4 | 613,000 | — | |
| Warrant value issued as part of Amended Term Loan | — | 319,000 | — | — | |
| Right of use assets obtained in exchange for lease liabilities | 6 | 2 | — | — | |
| Property and equipment included in accrued expenses and accounts payable | 332,000 | — | 58,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is enGene Therapeutics Inc.'s CIK number?
enGene Therapeutics Inc.'s SEC CIK number is 0001980845 (1980845). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find enGene Therapeutics Inc.'s SEC filings?
All of enGene Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did enGene Therapeutics Inc. last report earnings?
enGene Therapeutics Inc. (ENGNW) most recently filed an earnings 8-K with the SEC on Jun 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-270384). This is enGene Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is enGene Therapeutics Inc.'s most recent earnings 8-K?
enGene Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed Jun 15, 2026 under accession 0001193125-26-270384. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View enGene Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →